NCT03756896View on ClinicalTrials.gov

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

January 25, 2019

Primary Completion Date

June 24, 2025

Study Completion Date

June 30, 2026

Conditions
Plasma Cell Myeloma
Interventions
DRUG

Carfilzomib

Given IV

DRUG

Dexamethasone

Given PO

DRUG

Pomalidomide

Given PO

Trial Locations (1)

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Institutes of Health (NIH)

NIH

lead

Emory University

OTHER

NCT03756896 - Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma | Biotech Hunter | Biotech Hunter